Works matching IS 11738804 AND DT 2020 AND VI 34 AND IP 2
Results: 13
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 245, doi. 10.1007/s40259-020-00418-x
- By:
- Publication type:
- Article
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 235, doi. 10.1007/s40259-020-00416-z
- By:
- Publication type:
- Article
Anti-HIV-1 Antibodies: An Update.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 121, doi. 10.1007/s40259-020-00413-2
- By:
- Publication type:
- Article
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 183, doi. 10.1007/s40259-020-00406-1
- By:
- Publication type:
- Article
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 133, doi. 10.1007/s40259-020-00405-2
- By:
- Publication type:
- Article
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 209, doi. 10.1007/s40259-020-00404-3
- By:
- Publication type:
- Article
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 197, doi. 10.1007/s40259-019-00403-z
- By:
- Publication type:
- Article
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 225, doi. 10.1007/s40259-019-00402-0
- By:
- Publication type:
- Article
Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 149, doi. 10.1007/s40259-019-00401-1
- By:
- Publication type:
- Article
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date.
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 111, doi. 10.1007/s40259-019-00400-2
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL).
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 171, doi. 10.1007/s40259-019-00398-7
- By:
- Publication type:
- Article
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
- Published in:
- BioDrugs, 2020, v. 34, n. 2, p. 159, doi. 10.1007/s40259-019-00395-w
- By:
- Publication type:
- Article